|
|
||
Broadvector is a private Australian biotechnology company. The company’s mission is to develop promising life science technologies for the benefit of human health. Broadvector has entered into an acquisition agreement for the exclusive worldwide rights to develop a novel gene therapy technology platform. This new generation gene delivery technology has significant potential in the treatment of solid tumours such as prostate cancer and in the development of vaccines. The technology platform was originally developed by one of Australia’s pre-eminent research institutions. The first therapy derived from the platform technology is for the treatment of prostate cancer. A Phase I clinical trial has commenced in Australia in Sydney. The trial is being supervised by a worldwide leader in clinical trial management. Prostate cancer is the most common cancer and the second leading cause of cancer death among men in developed countries. On a global scale, approximately 500,000 new cases are diagnosed in males in the developed world each year. For further information please contact:
|